Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website http://www.gastrores.org

Original Article

Volume 7, Number 5-6, December 2014, pages 123-130


Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment

Tables

Table 1. Characteristics of Patients With Chronic Hepatitis C
 
BMI: body mass index; ALT: alanin aminotransferase; SD: standart deviation; CI: confidence interval. aLogarithmic transformation (base 10) was applied. Confidence intervals of geometric mean are computed using 1,000 bootstrap samples. bGenotypes were determined in 167 patients. c152 patients with liver biopsy, evaluated based on the Ishak score.
Gender, n (%)
  Female121 (65.1)
  Male65 (34.9)
Age (years), mean ± SD55.6 ± 10
BMI (kg/m2), mean ± SD27.3 ± 4.6
  Normal weight (< 25 kg/m2), n (%)55 (29.6)
  Overweight (25-29.9 kg/m2), n (%)95 (51.1)
  Obese (≥ 30 kg/m2), n (%)36 (19.4)
Viral load at baseline (IU/mL), geometric mean (95% CI)a854,053 (663,578 - 1,087,754)
  < 400,000 (IU/mL), n (%)56 (30.1)
  ≥ 400,000 (IU/mL), n (%)130 (69.9)
Genotype, n (%)b
  Genotype 1b145 (86.8)
  Genotype 422 (13.2)
Baseline ALT levels (IU/L), median (first to third quartiles)49.0 (34.0 - 69.0)
Liver necroinflammationc, median (first to third quartiles)5.5 (4.0 - 8.0)
Liver fibrosisc, median (first to third quartiles)2.0 (1.0 - 3.0)
Distribution of liver fibrosis, n (%)
  Mild (Ishak staging score 0 - 2)107 (70.5)
  Moderate (Ishak staging score 3 - 4)35 (23.0)
  Severe (Ishak staging score 5 - 6)10 (6.5)

 

Table 2. Patients Characteristics in Each IL28B Genotype Subgroup
 
VariablesC/C (n = 42)C/T (n = 98)T/T (n = 46)P
BMI: body mass index; ALT: alanin aminotransferase; SD: standart deviation; CI: confidence interval. aLogarithmic transformation (base 10) was applied. Confidence intervals of geometric mean are computed using 1,000 bootstrap samples. bGenotypes were determined in 167 patients. cCases with liver biopsy were evaluated based on Ishak score. d30 patients. e83 patients. f39 patients. Different superscripts in a row (x, y) indicate statistically significant difference between groups.
Age (years), mean ± SD53.3 ± 11.255.7 ± 9.257.5 ± 10.20.147
Male, n (%)17 (40.5)31 (31.6)17 (37)0.571
BMI (kg/m2), mean ± SD26.9 ± 4.327.7 ± 4.726.9 ± 4.60.446
Viral load at baseline (IU/mL), geometric mean (95% CI)a987,812 (571,056 - 1,811,751)905,147 (648,435 - 1,296,846)660,740 (406,456 - 1,055,059)0.503
Patients with baseline viral load < 400,000 IU/mL, n (%)18 (42.9)21 (21.4)16 (34.8)0.020
  Genotype 1bb, n (%)37 (97.4)73 (83.9)35 (83.3)0.091
  Genotype 4b, n (%)1 (2.6)14 (16.1)7 (16.7)
Baseline ALT levels (IU/L), median (first to third quartiles)50.0 (34.0 - 83.0)xy44.0 (29.0 - 59.0)x57.5 (37.0-87.0)y0.006
Liver necroinflammationc, median (first to third quartiles)6.0 (4.0 - 6.0)5.0 (4.0 - 8.0)6.0 (4.0 - 8.0)0.669
Liver fibrosisc, median (first to third quartiles)1.0 (1.0 - 2.0)x2.0 (1.0 - 3.0)y1.0 (1.0 - 3.0)xy0.023
Distribution of liver fibrosis, n (%)
  Mild (Ishak staging score 0 - 2)25 (83.3)d53 (63.9)e29 (74.4)f0.236
  Moderate (Ishak staging score 3 - 4)5 (16.7)d23 (27.7)e7 (17.9)f
  Severe (Ishak staging score 5 - 6)0 (0.0)d7 (8.4)e3 (7.7)f

 

Table 3. Distribution of IL28B rs12979860 C/T Genotypes and Alleles in Patients With Sustained Virologic Response and Non-Responder
 
IL28BSVR (n = 83), n (%)Non-response (n = 103), n (%)POR (95% CI)
SVR: sustained virologic response; OR: odds ratio; CI: confidence interval.
rs12979860 allelesC98 (59)84 (41)< 0.001-
T68 (41)122 (59)< 0.001
rs12979860 genotypesCC28 (66.7)14 (33.3)0.0011
CT42 (42.9)56 (57.1)0.38 (0.18 - 0.80)
TT13 (28.3)33 (71.7)0.20 (0.08 - 0.49)

 

Table 4. Relationship Between IL28B Genotype and Response to Treatment Rates
 
Variables, n (%)C/C (n = 42)C/T (n = 98)T/T (n = 46)P
RVR: rapid virological response; cEVR: complete early virological response; EVR: early virological response; pEVR: partial early virological response; ETR: end-of-treatment response; SVR: sustained virological response; PR: partial response; NR: null response. aFive patients were not evaluated for RVR.
RVR23 (54.8)39 (41.9)a18 (39.1)0.216
cEVR37 (88.1)57 (58.2)22 (47.8)< 0.001
EVR (cEVR + pEVR)41 (97.6)71 (72.4)29 (63.0)< 0.001
ETR38 (90.5)61 (62.2)26 (56.5)0.001
SVR28 (66.7)42 (42.9)13 (28.3)0.001
Relapse11 (26.2)20 (20.4)14 (30.4)0.400
PR1 (2.4)8 (8.2)3 (6.5)0.443
NR1 (2.4)25 (25.5)16 (34.8)0.001
Breakthrough1 (2.4)3 (3.1)0 (0.0)0.495